<DOC>
	<DOCNO>NCT01669252</DOCNO>
	<brief_summary>This prospective , non-randomized , open-label , multicenter , single-arm exploratory pharmacogenomic study single agent eribulin neoadjuvant therapy patient operable Stage III HER2 non-overexpressing breast cancer .</brief_summary>
	<brief_title>Pharmacogenomic Study Neoadjuvant Eribulin HER2 Non-overexpressing Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Written inform consent , specifically highlight molecular characterization tumor genomic sample Age ≥18 year Histologically confirm invasive breast carcinoma , follow characteristic : Primary tumor ≥2cm large diameter ( cT13 ) cN01 No evidence distant metastasis ( M0 ) Breast cancer ( BC ) eligible primary surgery Available pretreatment core ( Trucut ) biopsy possibility perform one HER2negative BC ( per local assessment ) , define either follow : 01+ expression IHC 2+ expression IHC situ hybridization ( FISH/CISH ) without HER2 gene amplification ( &lt; 4 HER2 gene copy per nucleus , FISH ratio [ HER2 gene copy Cr17 signal ] &lt; 1.8 ) Is situ hybridization ( FISH/CISH ) without HER2 gene amplification , independently IHC Known hormone receptor ( ER/PgR ) status ( per local assessment ) possibility perform test Known percentage hormone receptor ( ER/PgR ) Ki67positive tumor cell ( per local assessment ) , possibility perform test In case multifocal tumor , large lesion must ≥2 cm designate `` target '' lesion subsequent tumor evaluation HER2negative status must document tumor foci ECOG performance status 0 1 Laboratory value follow : Absolute neutrophil count ( ANC ) ≥1.5 x 109/L Platelets count ≥100 x 109/L Hemoglobin ≥9 g/dL Serum bilirubin ≤1.5 time upper limit normal ( ULN ) Alanine aminotransferase aspartate aminotransferase ( AST ) ≤2.5 x ULN Alkaline phosphatase ≤2.5 x ULN Serum creatinine ≤1.5 mg/dL calculate creatinine clearance ≥60 mL/m Absence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule Ability willingness comply study visit , treatment , test , comply protocol Availability genomic DNA ( via whole blood ) Any prior treatment primary invasive BC Metastatic , locally advanced inflammatory ( i.e. , Stage IIIIV ) BC Bilateral invasive BC Multicentric BC , define presence two foci cancer different quadrant breast Preexisting peripheral neuropathy grade Uncontrolled hypertension ( systolic &gt; 150 mmHg and/or diastolic &gt; 100 mmHg ) Clinically significant ( i.e. , active ) cardiovascular disease Long QT syndrome Concomitant use inhibitor hepatic transport proteins organic aniontransporting protein , Pglycoprotein , multidrug resistant proteins etc Major medical condition might affect study participation ( e.g. , uncontrolled seizure disorder , uncontrolled pulmonary , renal hepatic dysfunction , uncontrolled infection ) Other primary malignant tumor within previous 5 year , except adequately control limited basal cell carcinoma skin carcinoma situ cervix Known human immunodeficiency virus ( HIV ) infection active serious infection require IV antibiotic randomization Pregnancy breastfeed woman Women childbearing potential ( &lt; 2 year last menstruation ) use effective , nonhormonal mean contraception study period 6 month follow last administration study drug Administration live virus vaccine within 8 week precede study entry Use investigational agent within 30 day administration first dose study drug concurrent treatment another clinical study Requirement radiation therapy concurrent study anticancer treatment Known hypersensitivity study drug excipients Inability unwillingness abide study protocol cooperate fully investigator designee</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Eribulin</keyword>
	<keyword>Neoadjuvant</keyword>
	<keyword>PAM50</keyword>
	<keyword>Triple-negative</keyword>
	<keyword>Luminal A</keyword>
	<keyword>Luminal B</keyword>
</DOC>